1147P Effects of the use of antibiotics or antacids on chemoimmunotherapy prognostic factors in patients with advanced non-small cell lung cancer: A propensity-score-matched analysis

Abstract

The gut microbiota is an immune-specific biomarker of cancer immunotherapy. Antibiotic- or antacid-induced dysbiosis negatively impacts clinical outcomes of immunotherapy. However, the impact of dysbiosis on the efficacy of chemoimmunotherapy, the standard of care in first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), remains unknown. Therefore, this study aimed to evaluate the impact of chemoimmunotherapy in patients with NSCLC exposed to antibiotics or antacids.